利用美国疾病控制与预防中心/美国食品药品监督管理局抗菌药物耐药性分离菌库进行检查点检查-MDR CT103XL检测的性能
Performance of the check-points check-MDR CT103XL assay utilizing the CDC/FDA antimicrobial resistance isolate bank.
作者信息
Powell Eleanor A, Haslam David, Mortensen Joel E
机构信息
Department of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Division of Infectious Disease, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
出版信息
Diagn Microbiol Infect Dis. 2017 Jul;88(3):219-221. doi: 10.1016/j.diagmicrobio.2017.04.011. Epub 2017 Apr 28.
The Check-MDR CT103XL beta-lactamase assay was validated for use in the clinical microbiology laboratory using two CDC-FDA Antimicrobial Resistant Isolate Bank panels (133 gram-negative bacilli known beta-lactamase genes). The CT103XL detected most reported resistance genes (123 of 136 genes) and additionally identified several resistance genes not reported by the CDC. Discrepant results were confirmed via whole genome sequencing.
使用两个美国疾病控制与预防中心-美国食品药品监督管理局抗菌药物耐药分离株库面板（133株已知β-内酰胺酶基因的革兰氏阴性杆菌），对Check-MDR CT103XLβ-内酰胺酶检测方法在临床微生物实验室的应用进行了验证。CT103XL检测到了大多数报告的耐药基因（136个基因中的123个），并额外鉴定出了几个美国疾病控制与预防中心未报告的耐药基因。通过全基因组测序对不一致的结果进行了确认。
Zotero 插件